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Abstract: Understanding the cellular target structure and thereby proposing the best delivery system to achieve sustained 
release of drugs has always been a significant area of focus in biomedical research for translational benefits. Specific tar-
geting of the receptors expressed on the target cell represents an effective strategy for increasing the pharmacological effi-
cacy of the administered drug. Liposomes offer enhanced conveyance as a potential carrier of biomacromolecules such as 
anti-cancer proteins, drugs and siRNA for targeting tumour cell death. Commonly used liposomal constructs for various 
therapies are Doxil, Myocet, DepoCyt and Abraxanes. However, recent strategy of using multifunctional liposomes for 
the sustained release of drugs with increased plasma residence time and monoclonal antibody-based targeting of tumours 
coupled with imaging modalities have attracted enormous scientific attention. The ability of liposomes coated with spe-
cific ligands such as Apo-E derived RGD R9 and Tat peptide, to reverse the conceptualisation of drug resistance and cross 
the blood brain barrier, provides promising future for their use as an efficient drug delivery system. By outlining the re-
cent advancements and innovations in the established concept of liposomal drug delivery, this review will focus on the 
multifunctional liposomes as an emerging novel lipid based drug delivery system.
Keywords: Liposomes, multidrug resistance, immunoliposomes and gene transfer.
1. INTRODUCTION
 Research on lipids has increased rapidly in the past few 
decades due to significant advancements in biochemistry, 
metabolomics and systemic biology. Lipids belong to a di-
verse group of organic molecules that are characterised by 
their solubility in non-polar solvents and water. These bio-
logical entities constitute the cell membrane for two main 
functions; storage and regulation of gene expression [1]. 
Storage lipids are the primary component of a fat tissue con-
stituting about 99% of the volume. On the other hand, mem-
brane lipids consist of two non-polar acyl groups and one 
polar head group [2]. The cell membrane is constituted of 
lipid bilayer and series of proteins. The mechanistic working 
of the membrane relies on the role of lipids for its non-
permeable nature and proteins for information transduction 
from the outer environment to internal organelles [3]. Look-
ing back in evolution, the first proposed form of life was able 
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to produce the simple lipid vesicle with phospholipids [4]. In 
highly evolved eukaryotes, bilayer is made of phospholipids, 
sphingomyelin, and cholesterol. Within the phospholipid 
groups, phosphatidyl serine; phosphatidyl choline; phos-
phatidyl ethanolamine and phosphatidylglycerol determine 
specific biological functions [5]. Therefore, nanoformula-
tions can be synthesised to mimic these natural constructs 
and one such example is liposomes. Liposomes are spherical 
phospholipid bilayer constructs which close upon themselves 
to form a vesicle of colloidal dimension. This sequesters the 
hydrophilic end of the phospholipid molecule to face out-
wards making them water soluble while hydrophobic tails 
interact with bilayers. This chemical nature of liposomes can 
be exploited to possess uniform particle size distribution 
within the range of 20nm-10μm. The physico-chemcial char-
acteristics of liposomes include bilayer phase behaviour, 
permeability, lamellarity, colloidal nature and charge den-
sity. Liposomes are known for their high solubilising nature 
for various degrees of compounds. In addition to the above 
mentioned characteristics, they also interact with lipid bi-
layer of cells [6]. To account for this property, liposomes are 
used as drug delivery vehicles to carry vaccines [7], enzymes 
[8], non-enzyme proteins [9], anticancer proteins [10] and 
immuno-stimulatory molecules [11]. They can be made bio-
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logically functional through the addition of antibodies, ap-
tamers [12] protein receptors, ligands and other biosensor 
molecules for targeted therapies. Multifunctional liposomes 
with theragnostic property are in focus for the establishment 
of safe and efficient tumour therapy. 
2. TYPES OF LIPOSOMES
 Copolymers are the building blocks of vesicles and have 
property to self-assemble when dispersed in solvents like 
water and tetrahydrofuran (THF) [13]. Depending on the 
phospholipid – water interface, liposomes are categorised 
into three types. Multilamellar vesicles (MLV) – this is con-
sidered to be the simplest construct obtained by mechanical 
dispersion of dry lipids in water. Small unilamellar vesicles 
(SUV) are generated by systemically mixing two similar 
block copolymer [poly (butylenes oxide)-co-poly (ethylene 
oxide) designated PBn PEm in water. Conventionally, SUV 
are prepared from MLV using sonication procedure at 4°C 
for about 3-4 weeks or by subjecting them to freeze thaw 
cycles to induce fusion forming large unilamellar vesicles 
(LUV) [14]. Recent advances in this field combined the use 
of lamellae-forming non-ionic block copolymers PB10 PE10 
with micelle-forming PB10PE18 in an aqueous solution. The 
self-assembled polysomes are then passed through filters 
with small pores to form nanoscaled liposomes. Presence of 
PE18 tail prevents the aggregation of the formed vesicles re-
sulting in stable structures [13]. In order to improve the drug 
carrying capacity of the liposomes, MLVs are covalently 
crosslinked with adjacent lipid head groups stacked in con-
centric circles to form interbilayer-crosslinked multilamellar 
vesicles (ICMVs). The resulting constructs retain the drug 
payload and releases it in a controlled manner in serum for 
over 30 days [15]. In order to boost the immune response, 
the immuno-stimulatory ligand B7.1 which facilitates T cell 
proliferation (CD80) [16] or monophosphoryl lipid A, 
(MPLA) can be used. ICMVs elicit a 10-fold increase in 
antibody titre when compared to the MLVs. To translate the 
above strategy in terms of research, Moon JJ et al. synthe-
sised ICMVs by using 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), anionic 1.2-di-(9Z-octadecenoyl)-
sn-glycero-3-phospho-(1’-rac-glycerol) (DOPG) and anionic 
maleimide-headgroup lipid 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-[4-(p-maleimidophenyl) butyra-
mide (MPB) in 4:1:5 molar ratio. Mg
2+
 cations were added to 
cause fusion between vesicles. Polar head groups in concen-
tric circles were linked covalently by dithiothreitol (DTT) to 
form cation salt bridges between lipid layers [15]. The above 
nano-carrier can be used for encapsulating TLR agonists, 
drugs, lipophilic and hydrophilic drugs (Fig. 1).
3. DELIVERY OF THERAPEUTIC CONSTRUCTS
 Two main divergent groups of gene carrier system have 
been developed. Firstly, viral vectors like adenovirus and 
retrovirus are widely used for their high transaction effi-
ciency both in vitro and in vivo. Adenoviruses are known for 
their high level of gene delivery and expression [17]. Despite 
their high transfection efficiency, they are not recommended 
for therapies due to their de-limiting factors such as immu-
nogenicity, random integration into the host chromosome 
and a limited amount of DNA/siRNA packaging. On the 
other hand, non-viral vectors offer many advantages. Polyca-
tion lipids are used to compact negatively charged DNA 
molecules to form polyplexes [18, 19]. These polyplexes 
exhibit efficient interaction with the cell membrane but fail 
in gaining high transfection efficiency. Though non-viral 
vectors offer low efficiency of gene transfer, they do not 
elicit an immune response and can carry a larger amount of 
DNA [20]. Chimeric vectors have also been constructed 
combining non-viral vectors and viral components. DNA 
loaded liposomes are fused with ultraviolet inactivated hae-
magglutinating virus to form 400-500nm in diameter parti-
cles that can efficiently transfer intact oligonucleotides to the 
nucleus [21]. Liposome based vectors are also employed for 
gene transfer in mesenchymal stem cells (MSC). MSC holds 
greater importance in several gene and cell based therapies. 
Liposomal vectors carrying DNA are utilised to enhance 
therapeutic efficacy of MSCs by directing the stable fusion 
of the constructs into genomic DNA. Transfected MSCs 
were shown to possess higher viabilities and recoveries with 
their inherent multipotency [22-24]. These collective aspects 
of non-viral methods attracted researchers to comply on the 
use of liposomal-based drug delivery. 
4. RECENT BREAKTHROUGHS IN CATIONIC AND 
ANIONIC LIPOSOMES
 Liposomes are considered as non-viral methods in gene 
delivery techniques and also considered to be a therapeuti-
cally efficient system in the case of both benign and malig-
nant tumours [25]. Depending on the net charge, they are 
classified as cationic, anionic, zwitterionic and non-ionic 
liposomes. Cationic lipids are amphiphilic molecules with 
one or more fatty acid side chains alkyl or acyl moiety and a 
linker with hydrophobic amino group. Positive charge on 
their polar head group aids in their interactions with nega-
tively charged DNA to form lipoplexes. Previously, 3-[N-
[(N’, N’ – dimethylamino)ethane]-carbamoyl]cholesterol 
[DC-Chol], N-[1-(2,3-dimyristyloxy)propyl]-N, N-dimethyl-
N-(2-hydroxyethyl) ammonium bromide and N, N, N-
trimethyl-2-bis[(1-oxo-9-octadecenyl(oxy]-(Z, Z)-1 pro-
panaminium methyl sulfate have been used to develop cati-
onic liposomes [26]. Many cationic compounds have been 
formulated due to the advent of N-[1-(2, 3-dioleyloxy) pro-
pyl] - N, N, N-trimethylammonium chloride [DOTMA] and 
1, 2-bis (oleyloxy)-3-(trimethylamino) propane [DOTAP] 
[27]. Cationic lipids are usually mixed with neutral lipids 
like dioleoylphosphatidylethanolamine [DOPE] to enhance 
the stability of liposomal structures at low pH in endosomal 
compartments [28]. Additionally, stabilizers like poly (L-
lysine) and protamine decrease the size of the lipoplex com-
plex and offer protection to the loaded DNA from nuclease 
activity [29]. Earlier studies were upon the use of DC-chol 
liposomes, but their use has become very limited because of 
their tendency to form large DNA/liposome complexes [30]. 
Recently, dioleolylphosphatidylcholine (DOPC), cholesterol, 
stearyl amine has gained importance in the field of intranasal 
delivery [31]. Some of the commercially available cationic 
liposomes like Lipofectamine 2000 and Oligofectamine sig-
nificantly increased the efficiency of gene transfer. Though 
cationic liposomes offer numerous advantages, they are inac-
tivated in serum. Additionally, they are cytotoxic to macro-
phages and monocyte-like U937 cells but not on 
Targeted Multimodal Liposomes for Nano-delivery and Imaging Current Gene Therapy, 2013, Vol. 13, No. 5    3 
 
Fig. (1). Preparation of liposomes:
A) Phospholipids are the main constituents of biological membrane in which the extrinsic and intrinsic proteins are embedded. Among the 
various structure of phospholipid, liquid crystalline phase is the biologically most relevant one. Liposome vehicles are constructed in 
tune with nature’s architecture for delivering the drug specifically. When lipids are suspended in water, they form MLVs with many lay-
ers of lipids. Conventionally, SUVs were prepared by sonicating the MLV constructs for about 3-4 weeks or by the addition of deter-
gents. Further freeze thawing and removal of Ca2+ leads to the formation of LUVs.  
B) In order to stabilise the reactive head groups of the lipids at mild conditions, ICMVs are constructed from MLVs via covalent crosslink-
ing of fused reactive head groups with DTT. This stable formulation has higher half-life in serum (30days).  
C) Due to the advent in polymer technology, uniform SUVs are prepared from PB-PE polymer by subjecting them into polycarbonate nan-
ofilters. All three types of liposomal constructs are used for the encapsulation of drug, siRNA and dendrimers to form functionalized 
liposomes. 
non-phagocytic T lymphocytes. This is due to the toxicity 
and down regulation of immuno-modulators like nitric oxide 
(NO) and tumour necrosis factor –  (TNF-) respectively by 
cationic lipids and DOPE. As individual components, DOPE 
and cationic lipids are non-toxic to macrophages, but the 
addition of DOPE to DOTAP and other cationic lipids in-
creases the toxicity profile. Macrophages non-specifically 
internalize larger amounts of particles like liposomes due to 
high phagocytic activity. Hence lower level of toxicity is 
observed with non-phagocytic cells when compared to peri-
toneal macrophages. However, incorporation of DNA and 
other cargo molecules marginally reduced the toxicity of 
cationic lipids but failed in non-specific down regulation of 
NO and TNF- [32]. To overcome this toxicity, anionic 
liposomes are used. Though DNA compaction with anionic 
lipids is not so simple due to the repulsive forces between 
phosphate group of DNA and anionic head groups, divalent 
cations like Ca
2+
, Ba
2+
, Mg
2+
 and Mn
2+ 
can be used to facili-
tate their assembly by negating the mutual repulsion [27]. 
Among the divalent cations, Ca
2+
 has higher transfection 
efficiency. It is mediated via accommodation of larger 
(DNA) charge per unit area in the Ca
2+ 
atom. In addition to 
this, it also enhances the uptake of lipoplexes via endocyto-
sis. The most frequently used anionic lipid is DOPG in com-
bination with DOPE. A study conducted by Patil SD et al. 
showed that though anionic liposomes were able to deliver 
the DNA cargo with similar efficiency as that of cationic 
liposomes, (Lipofectamine) the toxicity profile of anionic 
liposomes were significantly less when compared to cationic 
liposomes [33]. Despite these encouraging aspects in anionic 
liposomes, they lack stability when they encounter plasma 
lipoproteins due to the absence of cholesterol in the con-
struct. With the overall knowledge about anionic liposomes, 
they can be used for studies involving non-receptor mediated 
endocytosis. On the other hand, neutral lipids such as DOPE 
and DOPC have been extensively used for imparting higher 
transfection efficiency. The possible reason for the efficiency 
could be due to electrostatic interactions between DNA and 
neutral lipids at low pH. When used in combination with 
cationic lipid DOTAP, salt bridges are formed between the 
positive charged head groups of cationic lipid and a phos-
phate group of DOPE groups. This association enhances the 
affinity of DOPE to negatively charged DNA thus helping in 
the package of DNA helices of interest [34, 35]. In spite of 
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various debates on the use of cationic liposomes, they are 
considered to be the most efficient delivery system. 
5. ENCAPSULATION OF DRUGS INTO LIPOSOMES
 Liposomes represent a highly flexible group of delivery 
vehicle amenable for modification and encapsulation. A vast 
array of therapeutic compounds can be encapsulated within 
the liposomes. Maximum encapsulation is desired for its use 
as a delivery vehicle. The lipid bilayer is almost 8 - 10 nm 
thick and guards the cell against water, gases, sugars and 
proteins. Hence, exogenous hydrophilic substances have to 
be encapsulated inside the liposome for easy transport across 
the cell membrane. A very simple method of encapsulation is 
thin lipid film method. Lipids with random orientation are 
dissolved in water to form small degree of bilayer. On the 
addition of water with drug/antibiotics, lipid bilayers swell to 
form invaginations for efficient loading. These structures 
form the basis of MLVs with passive encapsulation of water-
soluble drugs [36]. Another method to encapsulate the drug 
is through freeze thawing technique. During the formation of 
LUVs from SUVs, distance between the lipid bilayer in-
creases allowing the drug to penetrate via the transient pores. 
A significant setback relates to the limited encapsulation 
efficiency with only 15-20% entrapment into the liposomal 
core [37]. Another technique previously used was ethanol 
injection. In this method lipid ethanol solution is forcefully 
injected into the drug solution to from vesicles with diameter 
dependent on the concentration of the lipid. Untrapped drug 
or protein is separated by a crossflow-ultradiafilteration unit. 
Various factors including the rate at which lipid encounters 
the drug, pressure, ethanol concentration and low encapsula-
tion profile have diverted the researchers to find an alterna-
tive high throughput technique to encapsulate the drug effi-
ciently [38]. Reverse phase evaporation technique and pH 
gradient method are highly preferable method. The pH gra-
dient loading of drug includes the use of basic solution like 
HEPES/NaCl buffer (pH7.5) to replace intra-liposomal solu-
tion of 300 mM citrate buffer or 300 mM sucrose/20 mM/15 
mM EDTA for MnSO4 and MnCl2 (pH3.5) [39]. The ammo-
nium sulfate method is used for encapsulating anthracycline 
drugs. In this case, liposomes are prepared in ammonium 
sulfate salt with pH around 5.5 and subsequently subjected 
for ammonium sulfate exchange through counter buffers 
with pH 7.4 to cause pH gradient. For every molecule of 
ammonia that is exchanged with its counter buffer, one pro-
ton is left to create pH gradient. This mechanism of salting 
out causes the gelation and flocculation of the encapsulating 
drug thus improving its efficiency [40]. Topotecan (TPT), a 
topoisomerase I inhibitor known for its use in cancer therapy 
has been successfully encapsulated within liposomes with 
90% efficiency [41]. Encapsulation efficiency also depends 
on the hydrophilic and hydrophobic nature of the drug. Hy-
drophilic drugs can be encapsulated within the aqueous 
component and lipophilic drugs within the bilayer. One of 
the favoured means of trapping drugs within liposomes is the 
microencapsulation vesicle technique. This strategy utilises 
phospholipids dissolved in organic solvent (chloroform) and 
water to form water/oil emulsion. Organic solvent is evapo-
rated to get liposomal suspension. Drugs like flurbiprofen, 
ibuprofen, ketoprofen and amitriptyline are added during the 
oil phase whereas, 5-fluorouracil and diclofenac sodium can 
be added in the water phase [42]. A versatile approach for 
loading drug that are fundamental in nature is through the 
ionophore-pH gradient method. Addition of ionophores such 
as nigericin or A23187 creates transmembrane gradients of 
Mg2+ and K+ for the transport of the drug into the 
liposomes. Ionophore addition shows strong dependence of 
retention on the drug to lipid ratio or intra-vesicular drug 
concentration improving the loading capacity. Biodistribu-
tion of three commonly used anticancer drugs - vincristine, 
vinblastine and vinorelbine had shown to increase when de-
livered in a liposomal carrier prepared using ionophore tech-
nique [43]. 
6. LIPOSOMES: AN AVENGER IN DRUG DELIVERY
 Liposomes have a decade long clinical presence as a 
nano drug delivery vehicle. Their hybrid constructs present 
considerable opportunities for combinatorial therapeutic and 
imaging modalities. The versatile nature of liposomes lies in 
their structural integrity which can efficiently carry drug into 
the cell. Currently used liposomal constructs for various 
therapies include Doxil/Caelyx [44-46], Myocet [47], Depo-
Cyt [48], DaunoXome [49], ONCO-TCS [50], GemLip [51], 
Abraxane [52, 53] and Navelbine IV [54]. Other common 
drugs like curcumin [55], resveratrol [56] and oxiplatin [57] 
are also used in combination with liposomes. To obtain the 
maximum benefit from liposomal delivery, certain modifica-
tions and covalent conjugations are needed. Polyethylene 
glycol moiety; construction of liposomes for triggered re-
lease and addition of antibodies for target specific delivery 
has been discussed in this review. 
6.1. PEGylated Liposomes
 Liposomes reach the target site of target either by active 
or passive targeting. Active targeting exploits the over-
expression of surface receptors in the cancer cells. By cou-
pling the liposomes with targeting ligands, particulate drugs 
can be delivered on to the local site. Passive targeting fo-
cuses on the use of non-targeting nanoparticles that have the 
ability to accumulate in the interstitial spaces of tumour cells 
mainly through enhanced permeability and retention effect 
[EPR]. Passive or physiologic targeting of tumours depends 
on the long circulating liposomes which have the ability to 
dodge and resist the uptake by reticuloendothelial cells [58]. 
When liposomes are delivered intravenously, they interact 
with both high-density lipoproteins and opsonins. Some of 
the opsonising proteins like complement; immunoglobulins 
enhance the interaction of liposomes with phagocytic cells 
like macrophages and dendritic cells [59]. The rate of clear-
ance from the blood stream depends on the ability of opson-
ins to bind to the liposomes. It was reported that opsonins 
bind to fluid liposomes more avidly than rigid lipid bilayers 
[6]. Additionally, the clearance also depends on size and 
charge of the liposomes [60]. Mode of delivery plays a vital 
role in biodistribution of liposomes. Intravenous delivery 
results in the accumulation of liposomes in liver, spleen and 
bone marrow. When administered subcutaneously or intra-
muscularly only a small proportion of liposomes accumu-
lated in the above sites. Most of the liposomes were arrested 
at the site of injection and attacked by immune cells [6]. To 
circumvent this and to increase the half-life of liposomes, 
polyethylene glycol is used. This PEGlyated or STEALTH 
Targeted Multimodal Liposomes for Nano-delivery and Imaging Current Gene Therapy, 2013, Vol. 13, No. 5    5 
liposomes circulate in the blood stream as stable constructs 
which can extravasate in the target tissue. They behave as 
biologically inert molecules with slow release of entrapped 
drug thereby increasing its bioavailability [60]. The main 
thrust to develop PEGylated liposomes is to increase the 
bioavailability of the encapsulated drug to the target tissue 
after local administration. The use of PEGylated liposomes 
also increases the pharmacokinetics of the therapeutic agent 
in various cancer models with target accumulation in mito-
chondria and caveolae [61]. Unlike other approaches, PEGy-
lation does not involve the covalent attachment of stabilising 
agents in the carrier vehicle. PEGylated liposomal doxorubi-
cin (DOXILR) is approved worldwide for treating advanced 
breast cancer, ovarian cancer, AIDS related Kaposi’s sar-
coma, hepatocellular carcinoma and multiple myeloma. In 
the U.S., PEGylated liposomal doxorubicin is used for the 
treatment of metastatic ovarian cancer that is refractive to 
conventional therapies such as paclitaxel- and platinum- 
based chemotherapies. Combinatorial treatment with vincris-
tine and reduced dose of dexamethasone had encouraging 
results in a phase II study. Conventionally, doxorubicin is 
administered at a concentration of 60-90mg/m
2
 every 3 
weeks, while liposomal delivery of the same drug accounts 
for 50mg/m
2 
administration every 4 weeks [62, 63]. Thus 
PEGylated liposomes serve as a better vehicle of particulate 
drugs in vitro for improved quality of life in the ovarian can-
cer patients. An additional benefit of PEGylated liposomes is 
that, they are used to treat inherited bleeding disorder hae-
mophilia. Prophylactic treatments for haemophilia have al-
ways been hampered by poor patient compliance. In addition 
to this, half-life of free FVIII [precursor for factor X] in se-
rum is only about 10-12 hours. A long lasting active form of 
FVIII would provide protection against bleeding. Therefore, 
PEGylated liposome composed of 1-palmitoyl-2-oleoyl 
phosphatidylcholine (POPC) and 1, 2 distearoyl-sn-glycero-
3-phosphatidylethanolamine-N-methoxy (polyethylenegly-
col)-2000 (DSPE-PEG2000) is used. PEG formulations of 
FVIII and FVIIa increased the survival rate and decreased 
the clotting time in haemophilia patients [64]. 
6.2. Stimuli Sensitive Liposomes
 A strategy to construct liposomes to sense the external 
stimulus for effective drug release intrinsically may improve 
the biodistribution and intracellular fate of the drug. Stimulus 
such as pH, temperature and redox microenvironment can 
trigger the release of drug from liposomal constructs. Pre-
cisely, acidic environment in solid tumours represents pH 
value of about 6.5 to the administered drug. The pH in cellu-
lar compartments like endosome and lysosomal vesicles are 
around 5.5 and 4.5 respectively imposing lower values than 
cytosolic pH. To surpass the lysosomal degradation, pH sen-
sitive liposomal constructs are used to deliver the cargo into 
cytosolic environment. As a proof of concept, liposomal 
formulation is destabilised in the endosomal compartment 
promoting the release of contents thus, preventing the further 
degradation at lysosomal levels. The mechanism of pH trig-
gered release depends on four factors; I) neutralisation of 
negative lipids in bilayer by protonation forming hexagonal 
phase, II) protonation of negative polymers and eventual 
absorption to the bilayer leading to destabilisation of the 
construct by the formation of pore and fusion, III) hydrolysis 
of lipid bilayer and IV) ionisation of neutral lipids to their 
positive and surface active conjugate acids [65, 66]. The first 
generation of pH sensitive liposomes were composed of 
phosphatidyl choline and N-palmitoyl homocysteine [67]. 
One of the interesting aspects of pH sensitive liposomes is 
their ability to mimic Listeria monocytogenes pathology. The 
bacterium utilises listeriolysin O (LLO) to escape the degra-
dation from endosome and lysosomal pathway facilitating 
the entry into the cytosol. A targeting strategy based on the 
use of LLO along with desired drug in a liposomal formula-
tion enhanced the protection of drug from plasma by increas-
ing the pharmacokinetics of the drug administered. Gelonin, 
a type I plant toxin is known for its antitumour activity and 
acts by inactivating the 28S ribosomal subunit. They belong 
to type I family of toxins with characteristic absence of B 
chain which can facilitate their entry into the cytosol. Hence, 
their bioavailability as a drug was of a major concern. Co-
encapsulation of LLO with gelonin in a pH sensitive 
liposome effectively delivered the toxin into the cytosol of 
the target cell [68]. On the other hand, temperature can also 
be used in initiating drug release from the liposome con-
structs. These thermosensitive liposomes undergo tempera-
ture-dependent phase transitions from gel to the liquid phase 
and become permeable at elevated temperatures, resulting in 
gradual release of the desired drug to the target cell [69]. 
Heating the tumour tissue to temperatures of around 43°C 
[mild hyperthermia (HT)] has been in practice for efficacious 
treatment in combination with chemotherapy. HT increases 
vascular permeation in solid tumours for accumulation of 
liposomes in the target area for controlled release of the 
cargo. To increase the half-life and membrane permeability, 
PEG and lysolipids or oligoglycerol are used. A lysolipid 
formulation “Thermodox” is currently used in combination 
with HT in patients with loco-regional breast carcinoma of 
the chest wall, and with radio frequency ablation in cases of 
metastatic liver cancer. First HT is given to improve tumour 
vascular permeability which can last for four hours, and 
upon the considerable accumulation of liposomes second HT 
is administered to trigger drug release from tumour localised 
liposomes [69, 70]. Doxorubicin has been widely encapsu-
lated in thermosensitive liposomes. Doxorubicin encapsu-
lated in lysolecithin containing thermosensitive liposomes 
can release the contents within 20 seconds at 42°C thereby 
increasing the bioavailability of the drug on the tumour site 
[71]. To improve the imaging capabilities of thermosensitive 
liposomes, dextran coated iron oxide nanoparticles are used. 
Iron oxide can serve as a heating source in an alternative 
magnetic field. This multivalent nanovehicle has the poten-
tial to combine targeted delivery and diagnosis with con-
trolled drug release property [72]. Magnetic forced driven 
transfection has been used as a new modality for delivering 
siRNA into target cells. Magnetofection using N, N’-
dioleylglutamide (DG) with cationic lipids and iron oxide 
nanoparticles substantially increases the cellular delivery of 
siRNA when compared to the commercially available 
Lipofectamine 2000 [73]. Introduction of plasmid DNA for 
IL-10 gene expression in the magentoliposomes aids the in-
hibition of plasminogen activator-1 responsible for vascular 
inflammation in cancer and atherosclerosis. This strategy has 
found significant application in transfecting highly sensitive 
HUVEC cells [74].
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6.3. Immunoliposomes
 Immunoliposomes also known as “guided missiles” can 
actively target the tissues through directed guidance provided 
by grafted molecules on their surface. This molecular finger-
print can either be an antibody itself or an antibody fragment. 
In order to compromise RES system, liposomes are engrafted 
with hydrophilic [PEG] or glycolipids [ganglioside: GM1]. 
The tagged molecules may increase the circulation time 
since they surpass hydrophobic interactions with immune 
cells. Taking advantage of PEGylated liposomes, tumours 
can be targeted via conjugation with antitumour antibodies. 
Tumours over-express antigens on their cell surface even in 
primary sites or during metastasis. Some of the antigens are 
shed in the blood stream and become soluble posing difficul-
ties in immunotherapies. Despite this difficulty, monoclonal 
antibodies [mAbs] have been successfully used to develop 
immunoliposomes for targeted therapy. One such example of 
mAb used in immunoliposomes is herceptin. Herceptin is a 
therapeutic antibody used for treating metastatic breast can-
cer by specifically targeting HER-2/neu protein. Engineered 
antibodies or chimeric mAbs do not elicit host immune re-
sponse when Fc fragment of the Ab is removed. Use of Abs 
enhances the cellular internalisation and efficiency of drug 
delivery presumably by enhancing the tumour cells for endo-
cytosis. Use of immunoliposomes constructed with the Fab 
portion of human anti-HER-2 fragment and doxorubicin, 
resulted in targeted distribution within the tumour bypassing 
passive accumulation in the interstitial space of the tumour 
cells [75]. Of late, research on the cell adhesion molecule for 
targeted therapy has gained enormous attention in the field of 
tumour immunology. Intercellular adhesion molecule 
(ICAM-1), a glycoprotein of the immunoglobulin superfa-
mily plays an important role in extravasation of tumour and 
in the inflammatory process mediating leukocyte binding to 
endothelium [76]. We carried out the elicitation of CTLs 
through using gene transfer of xenogenic ICAM-1 into EL-4 
lymphoma. In combination with 5, 6-dimethylxanthenone-4-
acetic acid (DMXAA), ICAM-1 therapy was capable of sup-
pressing the tumour size with increased cytotoxic T lympho-
cytes (CTL) and natural killer (NK) cell activation [77]. This 
study is of importance since the administered ICAM-1 gene-
mediated the antitumour immunity by overruling tumour 
mediated immunosuppression [78]. The strategy of deliver-
ing ICAM-1 gene through immunoliposomes for targeting 
endothelial cells in tumour could open a new window in fu-
ture therapeutics. In many inflammatory disorders such as 
rheumatoid arthritis, ICAM-1 remains the main target due to 
elicitation by cytokines such as TNF- and interleukin-1 (IL-
1). Increased expression of ICAM-1 is found in the synovial 
tissue due to the migration of leukocytes. Therefore, poten-
tial targeting mechanism by immunoliposomes to deliver 
bioactive compounds to the site of inflammation has been 
considered in several studies. A very recent study on the (1, 
2-distearoyl-sn-glycero-2-phosphocholine) [DSPC] and 1-[8-
[4(p-maleimidophenyl) butaroylamino]-3, 6-dioxaloctyl]-
2,3-distearyl-glyceryl-dl-ether [DSGE] lipids in conjugation 
with thiolated anti-ICAM (CD54) mAb was able to deliver 
the drug directly into the inflammatory site [77]. However, 
endocytic uptake of multivalent anti-ICAM conjugates and 
anti - ICAM coated nanoparticles were reported emphasising 
their utility in the successful delivery system [80]. In addi-
tion to ICAM-1, vascular cell adhesion factor (VCAM-1) is 
also over-expressed in tumour vessels. Anti VCAM-1 im-
munoliposomes display specific targeting of endothelial cells 
under static conditions with increased accumulation in target 
tumour vessels within 30 minutes to 24 hours. Very few anti 
VCAM-1 immunoliposomes migrate to other organs and are 
co-localised with macrophages. Immunoliposomes were pre-
pared from soy PC/cholesterol/cyanur-PEG2000/DiO with 
trace amounts of cholesteryloleylether with M/K-271 mAb 
for VCAM (Fig. 2). Monoclonal antibodies have been tagged 
with the above mentioned liposomes with special molecule 
cyanour-PEG2000-PE for conjugating the mAb to terminal 
ends of PEG [81]. With the advent of mAb against a range of 
angiogenic and cellular markers, this targeting strategy can 
aid in developing complete antitumour formulations. Expres-
sion of other biomarkers such as CD74 and glycoproteins in 
tumour microenvironment is also looked upon in order to 
achieve targeted therapy. CD74 is a type II transmembrane 
protein expressed on B cells and has recently been regarded 
as a target for antibody-mediated therapy. In relation to 
chronic lymphocytic leukemia, (CLL) CD74 is up-regulated 
with enhanced NF-kB and B cell proliferation. Milatuzumab 
drug when conjugated with cross-linking antibody against 
CD74 induced the cytotoxicity in vitro. Furthermore, incor-
porating milatuzumab in liposomes increased the drug 
bioavailability and cytotoxicity when compared to the free 
drug indicating that targeting through CD74 enhanced the 
activity of the drug on lymphoma cells [82]. Glycoproteins 
expressed on the tumour cells are a potential diagnostic 
marker as well as a target in cancer therapy. Over expression 
of mucin [MUC-4], a major cell surface glycoprotein in 
highly metastatic models of adenocarcinoma is due to up-
regulation of retinoic acid via TGF-2. Over- expression and 
cell altering properties of MUC-4 makes it a prognostic 
marker for targeting via gemcitabine loaded immu-
noliposomes with anti-MUC4 mAb (8G7). Lipid formula-
tions used for immunoliposome targeting MUC-4 include 
DSPC, DOTAP, cholesterol, DSPE-PEG2000, DOPE-
PEG2000-biotin. In order to increase the affinity of antibody 
to liposome, biotin conjugated mAb is added to neutravidin 
bound liposome. This strategy holds promise for cells ex-
pressing mucin glycoprotein during all stages of develop-
ment [83]. Inadequate oxygen supply to the tumour tissues 
results in hypoxic microenvironment rendering them refrac-
tive to chemotherapeutic drugs. Activation of downstream 
signalling pathways by hypoxia correlates with increased 
tumourigenesis in a variety of organs. Mitogen-activated 
protein kinase [MAPK], phosphoinositide 3 – kinase [P13K] 
and beta-catenin pathways are activated by Ron receptor and 
hypoxia inducible factor – 1 (HIF-1) resulting in tumour 
progression. Humanised antibody against RON generated 
with F(ab)2 fragment and conjugated with PEGylated 
doxorubicin loaded immunoliposomes are commonly used. 
Increased cytotoxic efficacy of anti-RON-DOX-
immunoliposome [Zt/g4 and Zt/c1] is attributed to antibody 
mediated RON activation, followed by endocytosis of RON-
immunoliposome [84]. For imaging purposes, both gadolin-
ium (MRI contrast agent) and quantum dots can be incorpo-
rated in the immunoliposomal constructs to facilitate multi-
modal targeting system through liposomes. 
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Fig. (2). Multimodal capabilities of liposomes
A) Tumours can evolve resistance to powerful candidate of drugs over a time due to the drug efflux mechanism. P-gp expression forms the 
baseline for this uncontrolled mechanism. Most of the administered drugs are pumped out by energy-dependent transporters eventually 
insensitivity to anticancer drugs. Since tumours cells express LDLR, liposomes are coupled to the listeriolysin O/ lipoproteins for effi-
cient drug delivery preventing the entry via transporters for drug resistance. Upon endocytosis, they directly release the cargo into the cy-
tosol escaping lysosomal degradation. Immunoliposomes constructed against VCAM-1/ICAM-1/HER/neu and MUC- 4 antigens have 
greater specificity with the related tumour. Targeted delivery is achieved through this guided missile which leads to decreased metasta-
sis, proliferation, metastasis and angiogenesis.  
B) Theragnostic liposomes have attracted many researchers to comply on this strategy. Stimuli sensitive liposomes with gadolinium (MRI 
contrast agent) immunoliposomes with quantum dots and SPIONS based dendrimers locked immunoliposomes are used for better imag-
ing strategy. Leaky vasculature in tumour milieu is utilised for the accumulation and entry of these nanoparticles. Local hyperthermia 
(42-43°C) results in the release of drug from the nanoparticles. Bio distribution of the drug can be monitored using MRI or quantum dot 
imaging systems. 
7. LIPOSOMES FOR REVERTING DRUG RESIS-
TANCE
 Although there have been remarkable breakthroughs in 
cancer therapy like chemotherapy and targeted drug delivery, 
several impediments such as drug transport, detoxification of 
glutathione conjugation, topoisomerases, DNA repair, Ras 
mutation and dysfunction in cell cycle - lead to drug resis-
tance in several tumour models. A well characterised bio-
marker involved in multidrug resistance (MDR) is P-
glycoprotein (P-gp) belonging to ATP-binding cassette i.e. 
ABC-transporter family [85]. The most frequently observed 
resistance for doxorubicin in cancer cells is due to the active 
efflux of the drug through P-gp. Use of P-gp inhibitors like 
verapamil, cyclosporine A and PSC 833 have limiting factors 
such as poor specificity and high toxicity. In order to cir-
cumvent the drug resistance, liposomal formulations are pre-
ferred since the free component of the drug is not available 
to cancer cells for up-regulating P-gp levels. When doxoru-
bicin is encapsulated in an anionic liposomal construct 
[Lipodox], it interacts with one of the drug-binding sites of 
P-gp and inhibits the efflux activity [86]. Drug resistance is 
also correlated to the higher content of cholesterol in the 
plasma membrane and increased expression of low-density 
lipoprotein receptor (LDLR). The candidate biomarker 
LDLR is utilised in targeted delivery of drug through 
liposomal formulations. Drug-loaded liposomes with recom-
binant LDLR binding peptide enhanced the cellular uptake 
of the nanoparticles through LDLR-mediated endocytosis 
circumventing P-gp mediated uptake. The efficacy of the 
above strategy can be enhanced by the use of simvastatin, 
which up-regulates LDLR levels and suppresses P-gp activ-
ity. Simvastatin reduces the endogenous level of cholesterol 
synthesis in drug resistant cell lines to impair the ATPase 
pump function [89]. Neutral lipids such as PC and PE are P-
gp substrates that compete with drugs for P-gp binding. 
PC/PE constituent liposomes increase the cellular uptake 
with enhanced cytotoxicity [84]. A second widely-used 
liposomal formulation for MDR condition is Daunoxome 
(DNX), which is a combination of daunorubicin (DNR) with 
distearoylphosphatidylcholine and cholesterol. Both DNX 
and free DNR were effective in non-MDR cases of tumour
8    Current Gene Therapy, 2013, Vol. 13, No. 5 Gurudevan et al. 
Table 1. Commercial and Conventional Liposomes Used in Drug Delivery 
Liposomes Trade Name Assignee Cancer Therapy Nanoparticle In vitro/ In 
vivo
References
Doxorubicin HCL 
liposome
Doxil/Caelyx Alza Corporation Ovarian cancer 
Kaposi’s sar-
coma;
Activation of 
complement;
liver cancer
DMPC, DMPG, EPC - 
PEGylated liposome;
RGDF peptide coupled 
to liposome;
Liposome/SiO2 /Au




SMMC-
7721
[38-40]
Doxorubicin Myocet Sopherion thera-
peutics
B cell non-
Hodgkin lym-
phoma
Egg phophatidylcho-
line/cholesterol
Patients 41
Cytarabine 
liposome
DepoCyt Enzon 
Pharmaceuticals
neoplasticmen-
ingitis
Choles-
terol/triolein/dOPC/DPP
G
Patients 42
Liposomal daun-
orubicin
Dauno Xome Gilead Science Relapsed menin-
geal acute mye-
loid leukemia
DOPC/Cholesterol Patients 43
Vincristine ONCO-TCS INEX Non-Hodgkin’s 
lymphoma
DOPC/cholesterol Patients 44
Gemcitabine GemLip - Pancreatic can-
cer
Hydrogenated egg 
PC/cholesterol
BxPC-3 and 
PSN-1
[45]
Paclitaxel Abraxane Abraxis Bio-
science
Breast cancer 
and ovarian 
cancer – 
multidrug resis-
tance
Albumin; liposome – 
EPC, CHOL, DOTAP
SKOV- 3;
SKOV-3TR
46, 47
Vinorelbine Navelbine IV Pierre Fabre 
Medicament
Squamous carci-
noma, non-small 
cell lung cancer 
and advanced 
breast cancer
Temperature sensitive 
liposome  (DPPC, 
MPPC, DSPE-PEG2000, 
EPC, CHOL)
A431 48
Curcumin - - Colorectal ade-
nocarcinoma,  
hepatocellular 
carcinoma, lung 
carcinoma and 
cervical cancer
DOPC and DLPC - 
PEGlyated
CT26, HT 
29, HepG2 
A549 and 
HeLa
49
Resveratrol - - Lung cancer DQA-PEG2000-DSPE A549 and 
drug resis-
tant cell 
A549/cDDP
[50]
Oxaliplatin - - Colorectal carci-
noma
PEG- liposome SW 480 51
 
but, DNX was found to be more effective in a MDR variant 
tumour condition emphasising the escape of the drug from 
pump action of P-gp [89]. For enhanced target specificity, 
arginine-glycine-aspartic acid peptide (RGD peptide) modi-
fied cationic liposomes represent an ideal vehicle. Sequential 
tailoring of doxorubicin and siRNA against P-gp with RGD 
peptide results in improved cytotoxicity with reversal of drug 
resistance [90]. Another crucial biomarker expressed in tu-
mour cells is “transferrin (Tf) receptors” Tf is a non-heme 
iron binding glycoprotein with high affinity for Tf receptors. 
To surpass P-gp mediated intake of the drug, liposomal car-
riers targeting Tf receptor-mediated endocytosis will feature 
the reversing of drug resistance mechanism. The importance 
of Tf receptors in targeted drug delivery is due to their high 
turnover rate in tumour cells for iron metabolism. A study by 
Kobayashi T et al. emphasises on the use of egg-PC/cholesterol
Targeted Multimodal Liposomes for Nano-delivery and Imaging Current Gene Therapy, 2013, Vol. 13, No. 5    9 
Table 2. Targeted Liposomes for Tumour Therapy 
S.NO Type of Liposome Composition of Lipids Therapeutic Protein/ligand Treatment/Cell Lines References
1. Immunoliposome DSPC and DSGE Anti-ICAM mAb HUVEC 73
2. PEG- Immunoliposome Soy PC/cholesterol/cyanur-
PEG2000/DiO and cholestery-
loleylether
M/K-271 mAb for VCAM Human Colo 677 
xenograft tumours
75
3 PEG- Immunoliposome HSPC:chol:mPEG2000-
DSPE:Mal-PEG
Milatuzumab Chronic lymphocytic 
leukemia
76
4. Immunoliposome DSPC, DOTAP, cholesterol, 
DSPE-PEG2000 and DOPE-
PEG2000
Anti-MUC4 mAb Glioblastoma [U-87MG]; 
pancreatic adenocarci-
noma [HPAF-II and Ca-
pan-1] and pancreatic 
ductal carcinoma [PANC-
1].
77
5. Immunoliposome HSPC:chol:mPEG2000-DSPE Anti-RON mAb – Zt/c1 and 
Zt/g4.
T-47D, MCF-7, SW620, 
SW837, HCC1937
78
6. PEGlyated DSPE-PEG2000-PC FVIII and FVIIa Haemophilia [58]
7. PEGylated PEGylated liposomal doxoru-
bicin
Cyclophosphamide and 
trastuzumab
Pilot study on humans for 
efficacy and cardiac safety

8. pH sensitive PE and CHEMS Gelonin/LLO Murine melanoma 62
9. PEGylated-Thermosensitive PAA - lysolecithin Doxorubicin Squamous carcinoma 65
10. Thermosensitive – iron 
oxide
DPPC and DSPC Carboxyfluorescein - 
11. Magnetic-lipoplexes BPEI-SPION pDNA for IL-10 HUVEC and prostate 
cancer
68
 
or hydrogenated egg PC/cholesterol covalently coupled with 
Tf for the delivery of doxorubicin. Tf receptor targeted cells 
showed substantial uptake of liposomes with the reversal of 
drug efflux by P-gp [91]. Solid tumours that remain robust 
for various chemotherapeutics can also be targeted via folate 
receptors. Folate receptors can be tethered via folate-hapten 
conjugates coupled with methotrexate for enhancing the im-
munity against tumour. A commonly used copolymer for 
folate targeting is poly (lactide-co-glycolide)-D-a-tocopheryl 
polyethylene glycol succinate and D-alpha-tocopheryl poly-
ethylene glycol succinate – COOH. Yet another interesting 
approach for tumour targeting circumventing drug resistance 
is use of cell surface glycans expressed on the plasma mem-
brane. Lectins represent the second generation of bioadhe-
sive molecules capable of recognising cell mucosal surface 
receptors. They bind specifically to the carbohydrate moiety 
expressed in the tumour environment [92]. A recent study on 
statin (3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor) 
reduces the efflux activity in Pgp/ABCB1 (ATP-binding 
cassette) and BCRP/ABCG2 (breast cancer resistance pro-
tein) transporters and increases the expression of LDLR in 
glioblastoma. Statin, in combination with LDL receptor tar-
geted liposome encapsulating doxorubicin was effective in 
delivering the drug which is otherwise non-permeable and 
does not cross the blood brain barrier. This nanoformulation 
elicited nitric oxide synthesis by statins and decreased the 
activity of MDR transporters [93]. Other biomarkers such as 
vascular endothelial growth factor receptor, integrin recep-
tor, cell adhesion molecule receptor and prostate specific 
membrane antigen can be employed for targeted delivery 
[94]. To combine the tumour sensitisation and drug resis-
tance; targeting of P-gp and hypoxia in solid tumour is an 
essential factor. Administration of anti-hypoxia inducible 
factor (anti-HIF) compounds and toll-like receptor agonists 
which regulates HIF signalling can be efficiently delivered 
through liposomes through Tf conjugation (unpublished data 
by our group) [95, 96]. 
8. LIPOSOMES FOR ENHANCEMENT OF IMMU-
NITY
 As the roles of both antigen-presenting cells and mono-
nuclear phagocytic system (MPS) have been well studied, 
strategy to target these cell types holds importance therapeu-
tically. The initial impact of inflammation in diseases includ-
ing asthma, atherosclerosis, cancer and pathogenic diseases 
such as human immunodeficiency virus (HIV) is targeted via 
MPS. Though targeting MPS poses difficulties, they repre-
sent a highly attractive group for improved therapeutic ef-
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fect. Liposomes have been widely investigated as a delivery 
system for phagocyte targeted therapies due to their low im-
munogenicity, biocompatibility, cell specificity and drug 
protection capabilities. Upon infection, the host responds by 
branching into two defence mechanism: humoral and cellular 
immune response. Antibodies are produced against the 
pathogen to neutralise them and T cells are activated for pre-
senting the antigen to major histocompatibility complex 
(MHC) groups. The very basic immunology defines the 
presentation of extracellular antigens via MHC class II to 
CD4
+
T cells, whereas intracellular antigens are processed by 
MHC class I via CD8
+
T cells. For generating antitumour 
response, cytotoxic T lymphocytes (CTL) play a crucial role. 
To induce CTL responses, antigen must be processed by 
MHC class I pathway in APCs via cross-presentation. Our 
study on co-stimulatory molecules like B7-H3, B7-1 and 
ICAM-1 showed that they stimulated antitumour activity via 
CD8
+
Tcells accompanied by CTL activity [78, 97-99]. Con-
jugation of antigens in liposomes induces effective antiviral 
CD8
+
T cell responses against major viruses such as HIV, 
hepatitis C virus (HCV) and SARS coronavirus. An alterna-
tive to attenuated, heat inactivated, or subunit vaccines are 
the use of immunodominant CTL epitope, which is more 
effective to elicit CD8
+
T cell response against these viruses. 
Surface coupled CTL epitopes on liposomes along with 
CpG, a ligand of TLR 9 induced the proliferation of CD8
+
T 
cells [100]. Taken together, surface linked liposomal anti-
gens can be applicable for CTL based vaccines against vi-
ruses that evade humoral immunity by altering their surface 
proteins and robust cancer cells. In the research point of 
view, liposomes can also be used to create macrophage de-
pleted organ or tissue in an animal by employing clodronate 
liposomes. At the therapeutic level, application of the same 
is effective in autoimmune diseases, neurological disorders 
and in gene therapy. Clodronate (dichloromethylene diphos-
phonate) is a first generation anti-osteoporotic drug recently 
used in liposome mediated macrophage suicidal approach. 
Intravenous and subcutaneous injection of clodronate 
liposome depletes kupffer cells (largest population of macro-
phages in the body) and macrophages in draining lymph 
nodes [101]. Atopic keratoconjuctivitis (AKC) is a severe 
case of ocular blinding caused due to homing of immune 
reactive cells. Macrophage infiltration in conjunctiva respon-
sible for AKC was efficiently suppressed by systemic (intra-
venous) administration of clodronate liposomes [102]. Thus, 
liposomes can also be used to create localised immunosup-
pression and tolerance induction. 
9. CONCLUSION
 One of the most prolific areas in the study of drug deliv-
ery is focused on liposomes, due to their inherent ability to 
harness the cells to provide specific targeting and enhanced 
distribution of the drug. First generation liposomes enabled 
easy modifications in their structural skeleton yet did not 
alter the biological properties of the cell upon intravenous 
administration (which is the most widely used route in medi-
cal applications). Therefore, optimistic goals of using PEGy-
lated, stimuli sensitive and immunoliposomes yielded very 
encouraging results both in vitro and in vivo in many tumour 
models. Liposomes can also be used to deliver drugs into the 
lung through liposome aerosol. Oral applications of 
liposomes are at an infacy and rather limited because of the 
liposomicidal environment in stomach and the duodenum. 
FUTURE PERSPECTIVES
 Despite major advances in drug delivery, liposomes have 
been a preferred vehicle due to controlled release of poorly 
soluble anticancer drugs and many bio-macromolecules. For 
effective delivery of the desired targets, new strategies are 
followed like synthesis of asymmetric liposomal nanoformu-
lations using the inverted emulsion technique. Cationic lipids 
form the core so that the liposomes can accommodate larger 
negatively charged cargoes (siRNA/miRNA/aptamers/locked 
nucleic acid). Catioinc liposome DOTAP can be used to de-
liver siRNA against cathepsin S to hematopoietic stem cells 
aiding in their differentiation into dendritic cells for enhanc-
ing immunity. Liposomal delivery of microRNA-7 in epi-
dermal growth factor receptor over expressing lung cancer 
cells can be used to decrease the chemotherapeutic resistance 
to tyrosine kinase inhibitors significantly. Aptamer conju-
gated cisplatin-encapsulated multifunctional liposomes en-
abled cancer cell specific targeting and also increased the 
plasma residence time of aptamers. Use of neutral or anionic 
lipid nanoformulation on the other hand helps in escaping 
MPS that readily eliminates positively charged particles in 
the body. When these stable nanoformulations are adminis-
tered into the system, cancer cells internalize them via endo-
cytic pathways after enhanced permeability and retention 
(EPR) effect. To circumvent the lysosomal entrapment, 
hemolysin containing liposomes or pH sensitive lipids (cho-
lesteryl hemisuccinate – CHEMS) can be employed. The 
former escapes the lysosome by hemolysin’s lipid bilayer 
poration and disruption capabilities and the later becomes 
unstable at low pH. Hence the drug can be specifically given 
to the cytosol or nucleus. Further use of antibody conjuga-
tion to the above construct will enable targeted therapy with 
lowering multidrug resistance in cancers. 
EXECUTIVE SUMMARY
• Liposomes are lipid based closed self-assembled struc-
tures that can be employed to improve the pharmacoki-
netic profile of a drug and can also be used to reduce the 
side effects of antitumour drugs.  
• Multidrug resistance - A major phenomenon occurs due 
to efflux of free chemotherapeutic drugs by primary 
transporter proteins like P-gp, and ATP-binding cassette 
transporters.  
• Anionic liposomes with doxorubicin interact with one of 
the binding sites of P-gp and decrease the efflux activity. 
• Increased expression of LDLR due to multidrug resis-
tance phenomenon can be utilised to deliver the nano-
formulations through these receptors.  
• Immunoliposomes exhibit specific cytotoxicity against 
antigen over-expressing cancer cells. Antigen and anti-
body reactions are much preferred than any other inter-
actions enabling specificity.  
• Liposomes can also act as an adjuvant and hence they 
can be used to target dendritic cells to improve antitu-
mour responses.  
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